Skip to Main content Skip to Navigation
Journal articles

Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A French multicenter study.

Antoine Néel 1, * Benoît Henry 1 Sebastien Barbarot 2 Agathe Masseau 1 François Perrin 1 Claire Bernier 2 Xavier Kyndt 3 Xavier Puechal 4 Pierre-Jean Weiller 5 Olivier Decaux 6, 7 Jacques Ninet 8 Arnaud Hot 8 Achille Aouba 9 Leonardo Astudillo 10 Jean-Marie Berthelot 8 Fabrice Bonnet 11, 12 Jean-Marie Brisseau 13 Bérangère Cador 6 Fabienne Closs-Prophette 14 Thomas Dejoie 15 Jean-Dominique de Korwin 16 Robin Dhote 17 Renato Fior 9 Bernard Grosbois 6 Eric Hachulla 18, 19, 20 Pierre-Yves Hatron 18, 20 Henry Jardel 21 David Launay 18, 19, 20 Adrien Lorleac'H 22 Pierre Pottier 1 Guillaume Moulis 23 Jacques Serratrice 5 Amar Smail 23 Mohamed Hamidou 1
Abstract : The aim of this study is to assess the long-term effectiveness and safety of IL1Ra in Schnitzler syndrome (SchS). Between 2010 and 2012, we performed a nationwide survey among French internal medicine departments to identify SchS patients. We retrospectively analyzed the long-term efficacy and safety of IL1Ra and the outcome of patients that did not receive this treatment. Forty-two patients were included in the study, 29 of whom received IL1Ra. The mean age at disease onset was 59.9years. Disease manifestations included urticaria (100%), fever (76%), bone/joint pain (86%), bone lesions (76%), anemia (67%), and weight loss (60%). The monoclonal gammopathy was overwhelmingly IgM kappa (83%). The mean follow-up was 9.5years (range: 1.6-35). Two patients developed Waldenström's macroglobulinemia and one developed AA amyloidosis. All of the 29 patients who received IL1Ra responded dramatically. After a median follow-up of 36months (range: 2-79), the effectiveness remained unchanged. All patients remained on anti-IL-1 therapy. Twenty-four patients (83%) went into complete remission and five (17%) into partial remission. Three patients experienced grade 3-4 neutropenia. Six patients developed severe infections. No lymphoproliferative diseases occurred while on IL1Ra. When last seen, all patients without anakinra had an active disease with variable impact on their quality of life. Their median corticosteroids dosage was 6mg/d (range: 5-25). IL1Ra is effective in SchS, with a sharp corticosteroid-sparing effect. Treatment failures should lead to reconsider the diagnosis. Long-term follow-up revealed no loss of effectiveness and a favorable tolerance profile. The long-term effects on the risk of hemopathy remain unknown.
Document type :
Journal articles
Complete list of metadata

Cited literature [37 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Wednesday, October 8, 2014 - 12:02:54 PM
Last modification on : Friday, January 21, 2022 - 5:50:01 PM
Long-term archiving on: : Friday, January 9, 2015 - 10:50:12 AM


Files produced by the author(s)



Antoine Néel, Benoît Henry, Sebastien Barbarot, Agathe Masseau, François Perrin, et al.. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A French multicenter study.. Autoimmunity Reviews, Elsevier, 2014, 13 (10), pp.1035-1041. ⟨10.1016/j.autrev.2014.08.031⟩. ⟨hal-01072523⟩



Les métriques sont temporairement indisponibles